Genetic and pharmaceutical inactivation of LMP7 or LMP10 subunits is sufficient to elicit profound impacts on both ventricular hypertrophy and atrial fibrillation induced by Ang II infusion (Li et al., 2018, 2019; Xie et al., 2019, 2020). The gene discussed is AGT; the disease is Ventricular hypertrophy.